南方医科大学学报
南方醫科大學學報
남방의과대학학보
JOURNAL OF SOUTHERN MEDICAL UNIVERSITY
2013年
10期
1421-1426
,共6页
彭黎%李福喜%邵文凤%熊静波
彭黎%李福喜%邵文鳳%熊靜波
팽려%리복희%소문봉%웅정파
肿瘤干细胞%乳腺癌%组蛋白乙酰化酶抑制%Nanog
腫瘤榦細胞%乳腺癌%組蛋白乙酰化酶抑製%Nanog
종류간세포%유선암%조단백을선화매억제%Nanog
cancer stem cells%breast cancer%histone deacetylase inhibitor%Nanog
目的研究组蛋白乙酰化酶抑制剂曲古菌素A对乳腺肿瘤干细胞自我更新的影响;初步研究其抑制乳腺肿瘤干细胞自我更新的机制。方法悬浮培养乳腺癌细胞系MDA-MB-468、MDA-MB-231、MCF-7和SKBR3,用不同浓度曲古菌素A处理悬浮培养乳腺癌细胞7 d,用0.1%DMSO作对照;用次级细胞球形成率和乳腺癌细胞初级细胞球细胞中肿瘤干细胞即CD44+/CD24-细胞群的百分比评价曲古菌素A对乳腺癌干细胞自我更新的影响;乳腺癌细胞初级细胞球细胞中CD44+/CD24-细胞群的百分比用流式细胞仪检测,凋亡细胞百分比用Annexin-V法在流式细胞仪检测,Nanog、Sox2和Oct4 mRNA的表达用定量PCR法检测。结果100 nmol/L和500 nmol/L曲古菌素A均能部分抑制4个乳腺癌细胞系中肿瘤干细胞的自我更新,但10 nmol/L不行;500 nmol/L曲古菌素A诱导乳腺癌细胞初级细胞球细胞凋亡;曲古菌素A能下调乳腺癌细胞初级细胞球细胞Nanog和Sox2 mRNA的表达。结论曲古菌素A能部分抑制乳腺癌干细胞的自我更新,其机制与其能下调乳腺癌初级细胞球细胞Nanog和Sox2表达相关联,提示临床可用低浓度组蛋白乙酰化酶抑制剂和其他抗癌药物联用以便获得较好的乳腺肿瘤干细胞自我更新抑制效果,胚胎干细胞核心转录因子Nanog和Sox2可能作为肿瘤治疗的新靶标。
目的研究組蛋白乙酰化酶抑製劑麯古菌素A對乳腺腫瘤榦細胞自我更新的影響;初步研究其抑製乳腺腫瘤榦細胞自我更新的機製。方法懸浮培養乳腺癌細胞繫MDA-MB-468、MDA-MB-231、MCF-7和SKBR3,用不同濃度麯古菌素A處理懸浮培養乳腺癌細胞7 d,用0.1%DMSO作對照;用次級細胞毬形成率和乳腺癌細胞初級細胞毬細胞中腫瘤榦細胞即CD44+/CD24-細胞群的百分比評價麯古菌素A對乳腺癌榦細胞自我更新的影響;乳腺癌細胞初級細胞毬細胞中CD44+/CD24-細胞群的百分比用流式細胞儀檢測,凋亡細胞百分比用Annexin-V法在流式細胞儀檢測,Nanog、Sox2和Oct4 mRNA的錶達用定量PCR法檢測。結果100 nmol/L和500 nmol/L麯古菌素A均能部分抑製4箇乳腺癌細胞繫中腫瘤榦細胞的自我更新,但10 nmol/L不行;500 nmol/L麯古菌素A誘導乳腺癌細胞初級細胞毬細胞凋亡;麯古菌素A能下調乳腺癌細胞初級細胞毬細胞Nanog和Sox2 mRNA的錶達。結論麯古菌素A能部分抑製乳腺癌榦細胞的自我更新,其機製與其能下調乳腺癌初級細胞毬細胞Nanog和Sox2錶達相關聯,提示臨床可用低濃度組蛋白乙酰化酶抑製劑和其他抗癌藥物聯用以便穫得較好的乳腺腫瘤榦細胞自我更新抑製效果,胚胎榦細胞覈心轉錄因子Nanog和Sox2可能作為腫瘤治療的新靶標。
목적연구조단백을선화매억제제곡고균소A대유선종류간세포자아경신적영향;초보연구기억제유선종류간세포자아경신적궤제。방법현부배양유선암세포계MDA-MB-468、MDA-MB-231、MCF-7화SKBR3,용불동농도곡고균소A처리현부배양유선암세포7 d,용0.1%DMSO작대조;용차급세포구형성솔화유선암세포초급세포구세포중종류간세포즉CD44+/CD24-세포군적백분비평개곡고균소A대유선암간세포자아경신적영향;유선암세포초급세포구세포중CD44+/CD24-세포군적백분비용류식세포의검측,조망세포백분비용Annexin-V법재류식세포의검측,Nanog、Sox2화Oct4 mRNA적표체용정량PCR법검측。결과100 nmol/L화500 nmol/L곡고균소A균능부분억제4개유선암세포계중종류간세포적자아경신,단10 nmol/L불행;500 nmol/L곡고균소A유도유선암세포초급세포구세포조망;곡고균소A능하조유선암세포초급세포구세포Nanog화Sox2 mRNA적표체。결론곡고균소A능부분억제유선암간세포적자아경신,기궤제여기능하조유선암초급세포구세포Nanog화Sox2표체상관련,제시림상가용저농도조단백을선화매억제제화기타항암약물련용이편획득교호적유선종류간세포자아경신억제효과,배태간세포핵심전록인자Nanog화Sox2가능작위종류치료적신파표。
Objective To investigate the effect of tricostantin A (TSA) on self-renewal of breast cancer stem cells and explore the mechanisms. Methods Breast cancer cell lines MDA-MB-468, MDA-MB-231, MCF-7 and SKBR3 were cultured in suspension and treated with different concentrations of TSA for 7 days, using 0.1% DMSO as the control. Secondary mammosphere formation efficiency and percentage of CD44+/CD24-sub-population in the primary mammospheres were used to evaluate the effects of TSA on self-renewal of breast cancer stem cells. The breast cancer stem cell surface marker CD44+/CD24- and the percentage of apoptosis in the primary mammospheres were assayed using flow cytometry. The mRNA expressions of Nanog, Sox2 and Oct4 in the primary mammospheres were assayed with quantitative PCR. Results TSA at both 100 and 500 nmol/L, but not at 10 nmol/L, partially inhibited the self-renewal of breast cancer stem cells from the 4 cell lines. TSA at 500 nmol/L induced cell apoptosis in the primary mammospheres. TSA down-regulated the mRNA expression of Nanog and Sox2 in the primary mammospheres. Conclusions TSA can partially inhibit the self-renewal of breast cancer stem cells through a mechanism involving the down-regulation of Nanog and Sox2 expression, indicating the value of combined treatments with low-dose TSA and other anticancer drugs to achieve maximum inhibition of breast cancer stem cell self-renewal. The core transcriptional factor of embryonic stem cells Nanog and Sox2 can be potential targets of anticancer therapy.